Kestra Medical Technologies (KMTS) drew fresh attention after recent share price moves, with the stock last closing at US$27.74. Investors are weighing this performance against the company’s growth-focused cardiovascular device business.

The recent 9.77% 7 day share price return and 14.72% 30 day share price return suggest positive momentum is building for Kestra Medical Technologies, while the 73.81% 1 year total shareholder return indicates this strength has been in place over a longer stretch.

If the recent move in Kestra Medical Technologies has your attention, it can be helpful to see what else is performing strongly in related areas through 44 healthcare AI stocks.

After a sharp 1 year run and a share price near the latest analyst target of US$30, the question for Kestra Medical Technologies is whether to accept today’s terms or wait for a more comfortable entry as valuation gets unpacked next.

Most Popular Narrative: 90% Undervalued

The most followed narrative pegs Kestra Medical Technologies at a fair value of $28, which sits just above the last close at $27.74 and leans on ambitious long term assumptions.

The bearish analysts are assuming Kestra Medical Technologies's revenue will grow by 44.0% annually over the next 3 years.

The bearish analysts are not forecasting that Kestra Medical Technologies will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Kestra Medical Technologies's profit margin will increase from -138.4% to the average US Medical Equipment industry of 11.5% in 3 years.

Want to see what kind of revenue curve and margin shift would need to sit behind that fair value label? The narrative leans on sustained top line growth, improving unit economics and a future earnings multiple that assumes continued traction in wearable cardiac recovery. The exact mix of these assumptions is where the story gets interesting.

Result: Fair Value of $28 (UNDERVALUED)

However, Kestra Medical Technologies also faces the risk that slower payer contracting or limited clinical guideline changes could limit prescription growth and challenge the current fair value narrative.

Another View on Kestra Medical Technologies Valuation

The fair value narrative presents Kestra Medical Technologies as undervalued at around $28. However, on a simple P/S basis the stock trades at 17.1x, compared with a fair ratio of 3.9x, the US Medical Equipment average of 2.9x, and a peer average of 3x. That is a wide gap. Investors may ask whether this represents a margin of safety or a valuation stretch that leaves little room for disappointment.

Investors who want to see how this pricing compares with the underlying numbers can review the fuller breakdown in See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Given the mix of optimism and concern around Kestra Medical Technologies, it makes sense to look at the data directly and move quickly while sentiment is in flux. To see both sides of the story in one place, start with 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Kestra Medical Technologies?

If Kestra Medical Technologies has you thinking harder about your next move, do not stop with a single stock. Broader ideas can sharpen your portfolio decisions.

• Target potential value opportunities before the crowd by scanning companies on attractive terms with 51 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with generous and consistent payouts through 11 dividend fortresses.
• Prioritise durability by zeroing in on 88 resilient stocks with low risk scores that aim to limit downside while keeping you invested.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.